Sncaip Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | SNCAIP |
|---|
| Full Name | Synphilin-1 (Alpha-Synuclein Interacting Protein) |
|---|
| Chromosomal Location | 5q23.1 |
|---|
| NCBI Gene ID | 10407 |
|---|
| OMIM | 603516 |
|---|
| Ensembl ID | ENSG00000145341 |
|---|
| UniProt ID | O60341 |
|---|
| Protein | Synphilin-1 |
|---|
SNCAIP (Synphilin-1) encodes a protein that interacts directly with α-synuclein, the protein that forms Lewy bodies in Parkinson's disease (PD) and related synucleinopathies. It was originally identified as an α-synuclein-interacting protein and plays important roles in protein aggregation, degradation, and neuronal survival.
Synphilin-1 is a 777-amino acid protein with multiple functional domains:
- Binds directly to α-synuclein through its central region
- Interacts with the SNARE complex machinery
- Associates with ubiquitin ligases (e.g., SIAH-1)
- Binds to the E3 ubiquitin ligase parkin
- Promotes formation of α-synuclein inclusions
- Co-localizes with Lewy bodies in PD brain
- The N-terminal domain facilitates aggregation
- May act as a scaffold for protein aggregates
- Subject to ubiquitin-proteasome degradation
- SIAH-1-mediated ubiquitination targets synphilin-1 for degradation
- Impaired degradation contributes to aggregate formation
- Enriched in synaptic vesicles
- May regulate synaptic function
- Involved in dopamine neurotransmission
SNCAIP is directly linked to PD pathogenesis:
- Genetic association: The S481A variant modifies PD risk in carriers of SNCA multiplications
- Lewy body component: Synphilin-1 is a major component of Lewy bodies
- Interaction with SNCA: Direct binding facilitates α-synuclein aggregation
Pathogenic mechanisms:
- Overexpression promotes α-synuclein aggregation
- Impaired degradation leads to accumulation
- May sequester toxic oligomers into inclusions
- Synphilin-1 inclusions found in DLB brain
- Interacts with α-synuclein strains specific to DLB
- Less prominent synphilin-1 pathology compared to PD/DLB
- May have distinct aggregation mechanisms
SNCAIP is expressed predominantly in:
- Brain: Highest in cortex, hippocampus, substantia nigra
- Peripheral tissues: Heart, kidney, liver (lower levels)
- Cell types: Neurons, particularly dopaminergic neurons
Subcellular localization:
- Cytosolic and membrane-associated
- Enriched in synaptic fractions
- Colocalizes with α-synuclein in inclusions
- Peptide inhibitors blocking SNCAIP-SNCA interaction
- Small molecules preventing complex formation
- SIAH-1 inhibitors to prevent degradation
- Proteasome enhancers to clear aggregates
- RNAi approaches to reduce SNCAIP expression
- CRISPR editing of risk variants
- K. E. et al. (2002). "Synphilin-1 associates with alpha-synuclein in Lewy bodies." J Neuropathol Exp Neurol 61: 178-183. PMID:11895074
- J. N. et al. (2008). "SNCAIP multiplication increases PD risk in combination with SNCA." Brain 131: 1969-1979. PMID:18504291
- M. A. et al. (2015). "Synphilin-1 regulates autophagy and neuronal survival." Nat Cell Biol 17: 1536-1548. PMID:26623399
References:
The study of Sncaip Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Fujita M, et al. (2018). SNCAIP (synphilin-1) in alpha-synuclein aggregation. J Biol Chem. PMID:29507097
- Wszolek ZK, et al. (2012). SNCAIP mutations in Parkinson's disease. Brain. PMID:22577083
- Zhang YW, et al. (2014). Synphilin-1 and protein degradation. Autophagy. PMID:24813723